Return to homepagePandemic Pact

Developing an infrastructure and performing vaccine effectiveness studies for COVID-19 vaccine in the EU/EEA

Grant number: VMVPT20663

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $90,495

  • Funder

    Estonian Research Council

  • Principal Investigator

    Uusküla Anneli

  • Research Location

    Estonia

  • Lead Research Institution

    University of Tartu

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine logistics and supply chains and distribution strategies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Evaluating the real-world COVID-19 vaccine performance is critical for understanding the risks and benefits of vaccination programmes. Many factors impact real-world vaccine effectiveness (VE), including vaccine transportation and storage and how patients are vaccinated. In addition, people recruited to vaccine clinical trials are often young and healthy, and therefore different from those who will receive vaccines in the real world. Real-world VE studies can also answer questions about effectiveness by age-group and risk factors, duration of vaccine protection, protection against transmission, relative effectiveness of different vaccines, relative effectiveness of one versus two doses and their timings, and effectiveness of the vaccine against new strains of SARS-CoV-2. 3.1. General objective To measure product-specific COVID-19 vaccine effectiveness (VE) amongst hospital healthcare workers (HCW) eligible for vaccination against all laboratory-confirmed SARS-CoV-2 infection.